Full transparency: CRISP™ may not be superior to what you are doing now. This is especially true if your organization has been executing M&A transactions for a protracted period and has adequate staff and budget dedicated to the process.
On the other hand, if executing M&A initiatives in your organization suffer from any of the 10 items that Boston Consulting Group has recently determined cause problems for transactions, CRISP™ can mitigate 6.5 of them (*).
- Poor Integration Strategy and Execution *
- Cultural Misalignment *
- Inadequate Due Diligence *
- Overestimation of Synergies
- Lack of Clear Vision and Objectives *.5
- Overpaying
- External Factors
- Leadership and Management *
- Failure to Engage Key Stakeholders *
- Lack of Effective Communication *
Collaboration underpins Improving all these problems. Here’s what an actual colleague said when asked … §
The fastest way to determine whether your organization will benefit from adopting CRISP™ is to use the free AI-driven Initial Viability Tool to perform a “non-invasive” analysis and recommendation. Go there now -> CRISP™ IVT.
§ Colleague testimonials are in their own words (but not voices), edited for length, and rendered as avatars for confidentiality.